Whole chromosome instability (CIN) is a common feature of cancer cells and has been linked to increased tumor evolution and metastasis. Several studies have shown that the loss of the pRB tumor suppressor causes mitotic defects and chromosome missegregation. pRB is inactivated in many types of cancer and this raises the possibility that the loss of pRB may be a general cause of CIN in tumors. Paradoxically, retinoblastoma tumor cells have a relatively stable karyotype and currently the circumstances in which pRB inactivation causes CIN in human cancers are unclear. Here we utilize a fluorescence in situ hybridization-based approach to score numerical heterogeneity in chromosome copy number as a readout of CIN. Using this technique, we show that high levels of CIN correlate with the combined inactivation of pRB and p53 and that this association is evident in two independent panels of cancer cell lines. Retinoblastoma cell lines characteristically retain a wild-type TP53 gene, providing an opportunity to test the relevance of this functional relationship. We show that retinoblastoma cell lines display mitotic defects similar to those seen when pRB is depleted from non-transformed cells, but that the presence of wild-type p53 suppresses the accumulation of aneuploid cells. A similar synergy between pRB and p53 inactivation was observed in HCT116 cells. These results suggest that the loss of pRB promotes segregation errors, whereas loss of p53 allows tolerance and continued proliferation of the resulting, genomically unstable cancer cells. Hence, it is the cooperative effect of inactivation of both pRB and p53 tumor suppressor pathways that promotes CIN.
INTRODUCTION
Genomic instability is a feature of most tumor cells. 1 This change often includes a high frequency of whole chromosome gains and losses termed chromosome instability [2] [3] [4] [5] [6] (CIN). CIN, and the aneuploidy that results from CIN, have long been linked to advanced tumor grade, poor response to chemotherapeutics and tumor evolution. 3, [7] [8] [9] [10] [11] [12] [13] Numerous regulators of mitotic fidelity contribute to genome stability. Mutations affecting proteins that are directly involved in chromosome segregation and the mitotic checkpoint have been associated with hereditary cancers, and are observed in a subset of specific types of cancers. [14] [15] [16] [17] However, efforts to identify a mitotic protein that is commonly inactivated in sporadic tumors have been unsuccessful 3, 18, 19 and the genetic (or epigenetic) changes that cause CIN in the majority of cancers are not known. One of the confounding issues is that CIN is a complex phenotype. 20 For changes in chromosome number to be common in a population of tumor cells, these cells have to develop the persistent mitotic errors that promote whole chromosome mis-segregation, and they have to acquire an ability to tolerate an aneuploid genome. It is likely, therefore, that CIN is the compound effect of several changes, rather than the result of a single mutation.
Multiple studies have shown that the presence of wild-type p53 limits the proliferation of cells that experience chromosome segregation errors. [20] [21] [22] Although the p53 tumor suppressor is frequently inactivated in tumors 23 and the ability of p53 to suppress the proliferation of aneuploid and polyploid cells is well established in both tissue culture cells and tumor models, 24 attempts to demonstrate a significant statistical association between TP53 status and CIN in panels of human tumor samples have been unsuccessful. 25 A second tumor suppressor gene that has been linked to CIN is the retinoblastoma susceptibility gene (RB1). Inactivation of RB1 is an initiating event in retinoblastoma and patients that inherit a mutant allele of RB1 are predisposed to other cancers later in life. [26] [27] [28] Numerous studies have demonstrated that inactivation of the pRB pathway increases chromosome mis-segregation and promotes aneuploidy (reviewed in refs [29] [30] [31] [32] . However, a recent study has shown that retinoblastomas, paradoxically, have a relatively stable genome. 33 If pRB inactivation does indeed cause CIN and aneuploidy in tumor cells, then it is important to explain why retinoblastoma, a cancer that is triggered by homozygous mutation of RB1, apparently lacks these features.
Retinoblastomas are unusual: they are one of only a few types of tumors that routinely preserve wild-type TP53. It has been argued that p53 is functionally compromised in retinoblastomas by increased expression of MDMX. [34] [35] [36] Nevertheless, the fact that retinoblastoma retain an intact TP53 gene led us to hypothesize that the protein product might have sufficient activity to suppress aneuploidy. We speculated that it is the synergistic effects of pRB pathway defects (that undermine mitotic fidelity) and p53 inactivation (that allow aneuploid cells to proliferate) that promote CIN in other types of tumors.
Here we present several lines of evidence in support of this idea. Using two independent panels of tumor cell lines, we show that a high level of CIN correlates with the combined loss of p53 and pRB function. We show that retinoblastoma cells do indeed exhibit the mitotic defects and segregation errors that are seen following the depletion of pRB from primary cells and that are evident in CIN tumor cells. As evidence that the endogenous p53 protein is functional in retinoblastoma cells, we demonstrate that it is stabilized in response to DNA damage, and that it limits the accumulation of aneuploid cells. Together, these results indicate that the presence of an intact TP53 gene likely explains the stable karyotype of retinoblastoma cells. Moreover, we propose that the synergistic effects of pRB and p53 inactivation could provide a general mechanism to promote CIN in human tumors.
RESULTS
Combined p53 and pRB functional status is an indicator of CIN In a previously published characterization of the karyotype complexity of a subset of NCI lines, Roschke et al. 25 used chromosome copy number heterogeneity (numerical heterogeneity (NH)) to give a measure of whole chromosome instability. Although TP53 mutation is known to suppress the proliferation of aneuploid and polyploid cells, the authors noted that any potential link between p53 status and CIN failed to reach statistical significance. We reexamined this data using information from Sanger database (http://www.sanger.ac.uk) on the status of TP53, RB1 and CDKN2A (p16 INK4A /p14 ARF ) in this collection of cell lines. As previously described, TP53 status was not significantly associated with CIN, and this was true whether we considered TP53 status alone, or TP53 together with p14Arf. Similarly, the inactivation of pRB did not show a statistically significant association with CIN. For this, we assumed that pRB function is compromised in cell lines that are either homozygous mutant for RB1 or contain a homozygous deletion of p16
INK4A
. However, a significant association was observed between CIN and the lines that had both homozygous mutation of TP53 and inactivation of the pRB pathway (Supplementary Figure 1 ; Fisher test: P ¼ 0.0359). Almost half of the lines with lesions in both p53 and the pRB pathway exhibited high CIN. In contrast, only B16% of lines with lesions in only one of these tumor suppressor pathways were characterized as high CIN.
To test whether this association is evident in a second independent panel of cell lines, we examined a collection of nonsmall-cell lung cancer (NSCLC) cells. As described by Roschke and others, 37, 38 we used NH within a population as a marker of CIN. In these experiments, we quantified chromosome copy number in the NSCLC cell lines using centromeric fluorescence in situ hybridization (FISH) probes for at least two different chromosomes. The degree of NH was scored for each probe as the percent of cells differing from the modal chromosome copy number for a given chromosome in that population. Variation in chromosome copy number was similar for each chromosome scored in a single cell line, indicating that variations are unlikely to be caused by stable subclonal populations. In addition, the value of NH did not directly correspond to the ploidy of the cells, supporting the idea that it provides a measure of CIN-induced heterogeneity rather than a representation of the overall degree of ploidy (Supplementary Figure 2) .
To assess the status of the pRB or p53 pathways, we identified the cell lines with mutations or deletions of TP53, RB1 and p16/ CDKN2A. None of the NSCLC lines showed copy gains in CCND1, but several had copy gains in CDK6 and/or CDK4 (greater than eight focal gains of the respective gene) that are linked to the functional inactivation of pRB (Sanger database: http://www.sanger.ac.uk and Genomics of Drug Sensitivity in Cancer: http://www.cancerRxgene.org). As seen in the NCI panel of cell lines, we observed a correlation between NH and the combined inactivation of pRB and p53 in the NSCLC lines. Approximately 52% of cell lines with both pRB and p53 pathway lesions exhibited high NH, compared with only 21% of the lines with lesions in only one of these pathways ( Figure 1 ; Fisher test: P ¼ 0.0455).
In summary, in two independent panels of tumor cells the level of CIN (as measured by the degree of NH in the population of cells) correlated most strongly with the functional inactivation of both pRB and p53.
Retinoblastoma cell lines show evidence of chromosome segregation errors To directly test whether the inactivation of pRB and p53 synergistically promotes CIN, we took advantage of the fact that retinoblastoma cell lines characteristically carry loss of function mutations in RB1 but rarely mutate TP53. These cell lines provide an ideal experimental context to test whether p53 limits CIN following the loss of pRB.
Previously, we demonstrated that depletion of pRB from chromosomally stable, diploid cells induces high rates of chromosome mis-segregation and a marked increase in the heterogeneity of chromosome copy number (NH) within the population for any given chromosome. 39 This frequent, high rate of chromosome missegregation is consistent with that seen in chromosomally unstable cell lines. 40 Recently, we confirmed that xenografts of retinoblastomas display similar mitotic defects. 41 Surprisingly, however, these tumors were found to exhibit a relatively stable genome. To better understand this apparent contradiction, we analyzed a series of retinoblastoma cell lines for mitotic defects. All of the retinoblastoma lines analyzed displayed evidence of mitotic defects including decreased sister chromatid cohesion during mitosis and increased frequency of lagging chromosomes, compared with control cells 41 ( Figure 2a ). Y79 and Weri1 cells exhibited lagging chromosomes in 31 ± 6% and 35 ± 9% of all anaphase cells, respectively. However, interphase FISH analysis with probes specific for chromosomes 6, 8 and 16 showed only a moderate level of NH within the population for several retinoblastoma cell lines (Figure 2b ). Although measures of NH are increased over that seen in non-transformed, genomically stable control cells, they are significantly lower than that commonly seen in CIN lines that display a similar frequency of lagging chromosomes during anaphase. 42 Indeed, the level of NH measured in retinoblastoma lines is more consistent with that seen in control cells acutely depleted of pRB ( Figure 2b ).
Retinoblastoma cells are resistant to generation of aneuploidy Normal diploid cells have a very strong response to changes in ploidy and this restricts the proliferation of aneuploid cells that arise spontaneously in a population. Because of this, the induction of segregation errors, even at very high rates, is insufficient to elicit a corresponding increase in aneuploidy variation within a population. 20, 21 To determine how retinoblastoma cells respond to changes in aneuploidy, we induced a high rate of chromosome mis-segregation and assayed NH within the population over time. To induce mis-segregation, we used monastrol, a small-molecule inhibitor of the mitotic motor Eg5, that compromises mitotic spindle structure and promotes improper kinetochore-microtubule attachments. 43, 44 Upon drug washout, spindle structure is restored, but many chromosomes maintain merotelic kinetochore attachments, which promote mis-segregation.
This monastrol treatment and washout scheme promotes segregation errors in otherwise diploid cells. The induction of segregation errors, and the appearance of aneuploid cells was monitored using interphase FISH. In control cells (RPE1), the NH in the population (Figure 2c ) increased initially following monastrol treatment, but these newly generated aneuploid cells were rapidly depleted from the population. Chromosome segregation errors were also enhanced in U2OS and MCF7 cells, cell lines that display a high level of CIN. However, in contrast to the diploid non-CIN RPE1 cells, U2OS and MCF7 cells were tolerant of this increased aneuploidy and the subsequent increase in NH was maintained for several days. This is consistent with the published work showing differential responses of CIN and non-CIN cancer lines to the generation of aneuploidy. 40 As with both the CIN (U2OS, MCF7) and non-CIN (RPE1) controls, the monastrol treatment and washout scheme increased chromosome segregation errors in retinoblastoma Y79 cells. Y79 cells resembled the non-CIN (RPE1) control cells in that the newly generated aneuploid cells were not proficient for continued proliferation and the level of aneuploidy rapidly fell back to the basal level for the population. Similar results were observed with an additional retinoblastoma cell line (WERI1) and indicate that retinoblastoma cells are relatively resistant to aneuploidy.
Such intolerance of changes in chromosome copy number has been shown by several groups to depend on p53, such that the presence of p53 limits the proliferative capability of aneuploid and polyploid cells. 20, 21 Retinoblastomas retain wild-type TP53 but p53-dependent cell death has been proposed to be tempered by MDMX amplification in these tumors. [34] [35] [36] It is not known whether the response of the p53 pathway to all types of stimuli is similarly compromised in retinoblastoma cells and we therefore asked whether the p53 pathway is functional in retinoblastoma cell lines and whether it limits the accumulation of aneuploid cells.
First, to determine whether the p53 pathway can be activated in retinoblastoma cells lines, we examined the response of these cells to doxorubicin-induced DNA damage. Similar to control diploid cells, p53 was stabilized in response to experimentally induced DNA damage in retinoblastoma cell lines (Figure 3a ). This stabilization of p53 was sufficient to induce expression of the p53 target p21 (ref 45) (Figure 3b ). Interestingly, unlike diploid cells, retinoblastoma cell lines exhibit a low level of detectable p53 even when not treated with damaging agents. This suggests that the retinoblastoma cells may be experiencing consistent activation of a p53-dependent response (Figures 3a and c) , an observation that would be consistent with persistent errors in chromosome segregation in the population of cells.
Second, to test directly whether p53 limits aneuploidy in retinoblastoma cells, p53 was depleted from three retinoblastoma lines (Y79, Weril, RB355) and NH was scored using FISH (Figures 3c, e, f) . For comparison, we also assayed the effects of p53 depletion on the diploid RPE-1 cell line, when co-depleted with pRB (Figures 3d and f) . In each cell line, p53 depletion significantly increased the level of NH over the level observed before depletion (retinoblastoma cells) or in cells depleted of pRB alone (RPE line; Figure 3e ; supplementary Figure 3) . We conclude that p53 is capable of limiting NH in retinoblastomas.
p53 limits increased aneuploidy following pRB loss Among the potential interpretations of this data was the possibility that p53 status might increase the frequency or severity of mitotic defects resulting from the loss of pRB. To assess this and to determine whether functional synergy between pRB loss and p53 loss could be demonstrated using alternative experimental approaches in non-retinal cells, we measured the effects of p53 depletion on the mitotic defects that have previously been described in pRB-depleted cells. The depletion of pRB from genomically stable RPE-1 cells compromised sister chromatid cohesion and centromeric structure (Figures 4a-c) , as previously shown. 39 Neither of these defects were seen when p53 was depleted, and we observed no change in the appearance or severity of these defects when p53 was co-depleted with pRB. This indicates that the effects of p53 loss are either downstream of or independent of the effects of pRB loss on mitotic chromosome structure.
Next, we examined a matched pair of HCT116 cell lines that either retain p53 (p53 þ / þ ) or from which the endogenous p53 gene has been removed by gene targeting (p53 À / À ). 46 Depletion of pRB altered kinetochore structure to a similar degree in p53 þ / þ and p53 -/-cells, as expected (Figure 4d ). Consistent with work showing that loss of p53 alone is not sufficient for the generation of aneuploidy, 47 interphase FISH experiments demonstrated that p53 þ / þ and p53 À / À HCT116 cells exhibit a similar, low level of NH (Figure 4e ). The depletion of pRB from p53 À / À cells gave a dramatic increase in NH. In contrast, depletion of pRB from p53 þ / þ cells gave only a moderate increase in chromosome copy number changes. Collectively, these data support a model in which the loss of pRB causes changes in mitotic structures that promote chromosome mis-segregation, whereas p53 limits pRB-induced CIN by preventing the accumulation of aneuploid and polyploid cells.
DISCUSSION
Dual loss of pRB and p53 function promotes tumorigenesis in many tumor model systems. 34, 36, [48] [49] [50] p53 and pRB both regulate transcriptional programs that allow important cell fate decisions, and mutations in the pRb and p53 pathways have been shown to cooperate in a number of cellular processes. For example, both pRb and p53 contribute to cellular proliferation, including the regulation of cell cycle arrest, senescence and cell death in response to a myriad of cellular assaults. [51] [52] [53] [54] [55] [56] In addition, a Figures 1a-c) . Depletion of pRB from chromosomally stable hTERT-RPE-1 cells induced mitotic defects, including decreased sister chromosome arm cohesion (a), increased sister kinetochore distance (b) and defective anaphases (c). Depletion of p53 alone does not induce similar defects and co-depletion of pRB and p53 does not enhance defects seen following depletion of pRB alone. (d, e) Similarly, isogenic p53 þ / þ and p53
HCT116 cell lines do not show evidence of mitotic defects or high NH. Although depletion of pRB results in increased inter-kinetochore distances in both lines, a striking increase in NH/CIN is seen only in the p53 null line. *Po 0.05; **Po0.001; ***Po0.0001.
consequence of pRB loss of function and E2F misregulation is the stabilization and activation of p53, such that, although the pRB pathway has been corrupted, cell cycle arrest and apoptotic programming can be initiated in a p53-dependent manner. 57, 58 This is thought to be a major reason why both pRB and p53 pathways are commonly found mutated together in cancer. Here we describe an additional level of cooperation between pRB and p53. We show that these tumor suppressors collaborate to promote genome stability and that the combined inhibition of both pathways promotes CIN. Data presented here, along with work from others, [20] [21] [22] 29, 30, 59, 60 suggest that this cooperation is likely due to a role for pRB loss in corrupting mitotic fidelity, and a separate role for p53 loss in allowing tolerance and proliferation of aneuploid cells. This interpretation is consistent with data presented here and by others showing that loss of p53 alone is not sufficient to induce segregation defects. [20] [21] [22] This relationship between pRB and p53 in generating CIN is not unique, and instead, this model is consistent with numerous lines of evidence that show loss of p53 allows for the generation of CIN when chromosome segregation is induced by various mechanisms (reviewed in refs 24, 61) . This cooperativity provides a simple explanation for several mysterious observations: it explains why mutation of p53 alone is not a good predictor of CIN, why loss of pRB in retinoblastoma is associated with a genomically stable karyotype, and finally, as described below, this also provides an explanation as to why the described CIN expression signature contains many pRB-regulated gene products.
A unique gene expression signature has been derived for CIN cell lines, 62 however, it has been noted that many of the genes contained in this expression signature are E2F targets whose expression is deregulated following pRB loss. This may be interpreted as evidence that RB1 loss is fundamental to the generation of CIN, or given that many of these are cell cycle genes, simply that CIN cells are also highly proliferative. Indeed, comparison of the CIN gene expression signature with that derived for pRB loss 63 shows that 440% of the CIN signature genes are shared with the RB loss expression signature, with 5 of the top 10 most highly mis-expressed CIN signature genes also present in the RB-loss signature. Consistent with this significant overlap, independent analyses have shown that both the RB-loss expression signature and the CIN expression signature are similarly predictive of outcome in various cancers. 38, 63 Here we have shown that NH, an independent read-out of CIN, similarly correlates with pRB loss of function, suggesting that the overlap in expression signatures is more than just a coincidence of proliferative capacity and is instead an indication of a close relationship between pRB loss of function and CIN.
In our sample set, over 70% (10/14) of the NSCLC lines with high NH have obvious genomic lesions in both the p53 and pRB pathways. A potential caveat is that pRB may be functionally inactivated by changes that act upstream of the classical components. Hence, by considering only the cell lines that have mutation of RB1, CDKN2A or copy gains in CCND1 or CDK4/6, we might overlook cell lines that have compromised pRB function. We note that three of the cell lines in this study, including two of the four lines with a high degree of NH, but without obvious changes in core components of the pRB pathway machinery, have mutations in the SMARCA4/BRG1 locus, the protein product of which has been shown to impact on pRB function. 64 In addition, It is possible that several different binding partners may impinge on RB's regulation of chromosome stability. In the absence of a quantitative read-out for pRB function, and given that it is currently unclear which other gene mutations may impact on pRB's activity, it is conceivable that the functions of pRB that promote genome stability may be compromised in all of the lines with high NH.
Recent work has demonstrated that tumors with high levels of CIN are more likely to relapse following seemingly effective chemotherapeutics, 3, [7] [8] [9] [10] [11] [12] [13] suggesting that increased levels of CIN promotes tumor evolution. Two major limitations to applying our knowledge of the functional implications of CIN in tumors to patient treatment lie in the ability to identify which tumors exhibit CIN, and the ability to manipulate CIN in a therapeutically relevant manner. Limitations in characterizing CIN in patient samples stem from the fact that CIN is not a static state, and instead represents a rate of segregation errors. As such, many tools used in tissue culture to analyze such changes that occur over time are not amenable to fixed patient samples. Indeed, methods for scoring CIN in tumor samples are limited to techniques that include analysis of structural and NH by karyotype analysis and the presence of the CIN gene expression signature. However, gene expression data are not readily available for all patient samples and not all samples are amenable to cytogenetic analysis. Data presented here show that combined pRB and p53 mutational status is predictive of high CIN and may therefore serve as useful criteria in identifying tumors likely to be resistant to traditional treatments.
Given that loss of pRB function is widespread in cancer, changes in chromatid cohesion that corrupt mitotic fidelity following pRB loss are likely to be a major contributing factor to CIN in cancer. However, numerous other mitotic defects have similarly been described to compromise genome integrity (reviewed in refs. 24,61) and it is not yet known what proportion of the CIN seen in tumor cells can be attributed directly to the inactivation of pRB or to what degree pRB loss may cooperate with other defects to promote CIN. In addition, pRB's contribution to CIN can be tempered. Our results show that one example of this occurs when wild-type p53 is able to limit the proliferation of cells that experience segregation errors caused by the loss of pRB. It is clear that the increased genetic diversity that results from CIN may benefit tumor survival. However, at a cellular level, the presence of aneuploidy has also been shown to impose metabolic challenges and can be detrimental to cell proliferation. 61 As such, in cancers where loss of RB1 is an initiating event, as it is in retinoblastoma, it may be necessary to limit CIN so that the benefit of RB1 loss in tumor initiation is not outweighed by the limits to proliferation imposed by aneuploidy.
Increased CIN has been shown to promote drug resistance and tumor relapse. In addition, although moderate levels of CIN correlate with poor patient response, both low levels of CIN, and surprisingly, high levels of CIN have been shown to correlate with improved patient outcome, suggesting that manipulation of CIN will be of therapeutic value. Enhancing CIN may promote mitotic catastrophe and sensitize cells to death. However, in the absence of a mechanism to specifically target cancer cells, increased CIN may have detrimental and even cancer-promoting effects in normal, proliferating cells. An alternative approach would be to promote genome stability by suppressing CIN, thereby relieving cancer cells of a major adaptive mechanism and rendering them more sensitive to therapeutic treatments. To address the feasibility of this approach, we have examined the effects of re-introducing pRB into human or mouse osteosarcoma cells that are deficient for both RB1 and TP53. In these experiments, we observed that the reexpression of pRB was sufficient to suppress mitotic defects, even in the absence of p53 (Supplementary Figures 4a and b) . This suggests changes that contribute to CIN in RB1-deficient cells can be suppressed. However, to fully understand the functional relevance of pRB's role in regulating genome stability, and to identify novel therapeutic targets, it will be necessary to separate pRB's multifaceted roles in regulating cellular proliferation from those that regulate mitotic chromosome segregation. Together, these experiments raise the tantalizing prospect that drugable targets may be identified to specifically and efficiently stabilize the genome of CIN cancer cells, thereby rendering them more sensitive to traditional therapeutics. This is an important avenue for future exploration and will likely elucidate not only the functional relevance of pRB's contribution to CIN, but also the therapeutic value of manipulating CIN in tumors. 
MATERIALS AND METHODS

FISH, drug treatment and immunofluorescence
Cells were prepared and fixed, and a-satellite-specific probes for chromosomes 2, 6 and 8 or probes specific to the p and q arms of chromosome 16 (see Figure 4 ; Cytocell, Cambridge, UK; distributed by Rainbow Scientific Inc, Windsor, CT, USA) were hybridized as described previously. 39 NH was determined by scoring 100-500 cells per population for copy number of each of two to four individual chromosome probes for each of three independent experiments. The percent that a particular probe varied from the modal copy number of that probe in that sample was calculated. To minimize the risk of incorrectly characterizing stable subclones as random heterogeneity, variations greater than 20% for any particular copy number were not scored as part of the NH used as a readout of CIN. Chromosome segregation events were induced via addition of 100 mM monastrol (Sigma) for 16 h. Cells were then collected, washed three times with phosphatebuffered saline and re-plated for 1, 3 or 6 days as indicated before preparation for FISH and analysis of NH. DNA damage was induced in hTERT-RPE-1 and retinoblastoma lines by the addition of 100 ng/ml of Doxorubicin (Sigma) for 5 h, at which point whole-cell lysates were collected for analysis of p53 levels. For analysis of mitotic sister chromosome arm cohesion, human or mouse tissue culture cells were treated with 100 ng/ml nocodazole for 30 min before swelling in hypotonic buffer. To ensure similar mitotic timing of all spreads analyzed, samples were prepared in parallel, hypotonic treatments preceding fixation were brief (10 min), and no prior mitotic enrichment/arrest was additionally performed. For analysis of human cells, cells were prepared for FISH analysis as described above and slidebook software was used to measure inter-chromosomal distances, defined as the distance between the centers of replicated FISH foci. Measurements of inter-kinetochore distances were done as previously described 39 on methanol-fixed mitotic cells. Fifty to hundred measurements were made for each sample in each replicate. All measurements were performed for three independent experiments. All error bars represent standard errors (s.e.m).
Whole-cell lysates and/or fixed cell samples were collected at 24, 36 and/or 48 h post transfection unless otherwise indicated. For immunofluorescence, cells were cultured and transfected on glass coverslips, washed briefly with phosphate-buffered saline and fixed for 10 min in ice-cold methanol without additional pre-extraction. Subsequent antibody incubations and washes were done in TBS-BSA (10 mM Tris at pH 7.5, 150 mM NaCl, 1% bovine serum albumin). DNA was detected with 0.2 mg/ml 4 0 -6-diamidino-2-phenylindole (Sigma-Aldrich, St Louis, MO, USA). Coverslips were mounted with ProLong Antifade mounting medium (Molecular Probes, Eugene, OR, USA). Fluorescent images of fixed and live cells were captured with a Hamamatsu Orca AG cooled CCD camera (Hamamatsu Photonics, K.K. Hamamatsu, Japan) mounted on a Nikon TI/Yokagawa CSU-10 spinning-disk confocal microscope with a Â 100, 1.4 numerical aperture objective or a Hamamatsu EM CCD camera mounted on an Olympus IX81 microscope (Olympus Corporation, Toyko, Japan) with a Â 100, 1.4 numerical aperture objective. A series of 0.25-mm optical sections were collected in the z axis for each channel (4 0 -6-diamidino-2-phenylindole, fluorescein, Cy5, and/or Texas red). Selected planes from the Z-series were then overlaid to generate the final image. Antibodies used include: tubulin/dm1a (Sigma), Ndc80 (Novus Biologicals, Littleton, CO, USA), p53/DO-1 (Santa Cruz Biotechnology) and ACA (Antibodies Incorporated, Davis, CA, USA). The Student's t-test or Fisher exact test was used to calculate the significance of differences between samples as indicated.
